The current Trump administration is pursuing policies to reduce regulations and expenditures across government, including at HHS, the FDA, CMS and related agencies. These actions, presently directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional uncertainty for our business. These actions and proposals may, for example, include…directing HHS and other agencies to lower prescription drug costs through a variety of initiatives, including by improving upon the Medicare Drug Price Negotiation Program and establishing Most-Favored-Nation pricing for pharmaceutical products…
All entries for: Kyverna Therapeutics
May 15, 2025
Kyverna Therapeutics
Layoffs
Emeryville, CA
51-200 employees
Despite having what CEO Warner Biddle called an “exceptional start” to the year, Kyverna Therapeutics had to downsize by 16% in the first quarter. As of March 31, the biotech had 119 full-time employees, as per an SEC filing. The layoffs are part of Kyverna’s effort to “streamline” its operations and support the development of its late-stage pipeline, while also extending its cash runway into 2027, the biotech announced on Tuesday, alongside its first-quarter earnings report.
Disease Area: Immune Diseases, Multiple, Neurological Diseases, Rare Diseases
Drug Type: Biologic